title: Safety of antiobesity drugs.
abstract: Obesity is a major health problem worldwide. Although diet and physical activity are crucial in the management of obesity, the long-term success rate is low. Therefore antiobesity drugs are of great interest, especially when lifestyle modification has failed. As obesity is not an immediate life-threatening disease, these drugs are required to be safe. Antiobesity drugs that have been developed so far have limited efficacies and considerable adverse effects affecting tolerability and safety. Therefore, most antiobesity drugs have been withdrawn. Fenfluramine and dexfenfluramine were withdrawn because of the potential damage to heart valves. Sibutramine was associated with an increase in major adverse cardiovascular events in the Sibutramine Cardiovascular Outcomes (SCOUT) trial and it was withdrawn from the market in 2010. Rimonabant was withdrawn because of significant psychiatric adverse effects. Orlistat was approved in Europe and the United States for long-term treatment of obesity, but many patients cannot tolerate its gastrointestinal side effects. Phentermine and diethylpropion can only be used for less than 12 weeks because the long-term safety of these drugs is unknown. Ephedrine and caffeine are natural substances but the effects on weight reduction are modest. As a result there is a huge unmet need for effective and safe antiobesity drugs. Recently lorcaserin and topiramate plus phentermine have been approved for the treatment of obesity but long-term safety data are lacking.
authors.affiliation: Division of Clinical Pharmacology and Therapeutics, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
authors.forename: Bernard Man Yung
authors.initials: BM
authors.lastname: Cheung
authors.affiliation: Division of Clinical Pharmacology and Therapeutics, Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.
authors.forename: Tommy Tsang
authors.initials: TT
authors.lastname: Cheung
authors.affiliation: Division of Clinical Pharmacology and Therapeutics, Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.
authors.forename: Nithushi Rajitha
authors.initials: NR
authors.lastname: Samaranayake
keywords: antiobesity drugs; cetilistat; fenfluramine; lorcaserin; obesity; orlistat; phentermine; rimonabant; sibutramine; tesofensine
references.citation: Drug Saf. 2003;26(14):1027-48
references.pmid: 14583064
references.citation: N Engl J Med. 2003 May 22;348(21):2074-81
references.pmid: 12761364
references.citation: Int J Obes. 1989;13 Suppl 2:39-46
references.pmid: 2613427
references.citation: Int J Obes (Lond). 2009 Aug;33(8):857-65
references.pmid: 19564877
references.citation: JAMA. 2006 Feb 15;295(7):761-75
references.pmid: 16478899
references.citation: JAMA. 2003 Apr 9;289(14):1837-50
references.pmid: 12684364
references.citation: Am J Med Sci. 2005 Oct;330(4):157-60
references.pmid: 16234606
references.citation: CNS Spectr. 2003 Aug;8(8):584-8
references.pmid: 12907921
references.citation: Lancet. 2005 Apr 16-22;365(9468):1363-4
references.pmid: 15836868
references.citation: N Engl J Med. 2010 Jul 15;363(3):288-90
references.pmid: 20647205
references.citation: BMC Med Genet. 2007 Sep 19;8 Suppl 1:S18
references.pmid: 17903300
references.citation: N Engl J Med. 2010 Sep 2;363(10):905-17
references.pmid: 20818901
references.citation: JAMA. 2003 Jan 1;289(1):76-9
references.pmid: 12503980
references.citation: Nat Rev Drug Discov. 2009 Nov;8(11):833-4
references.pmid: 19876031
references.citation: Diabet Med. 2005 Dec;22(12):1737-43
references.pmid: 16401321
references.citation: Nat Rev Drug Discov. 2004 Sep;3(9):771-84
references.pmid: 15340387
references.citation: Int J Obes Relat Metab Disord. 2000 Feb;24(2):144-50
references.pmid: 10702763
references.citation: JAMA. 1986 Jul 4;256(1):51-4
references.pmid: 3712713
references.citation: J Pharmacol Exp Ther. 2008 May;325(2):577-87
references.pmid: 18252809
references.citation: J La State Med Soc. 2005 Jan;157 Spec No 1:S50-5
references.pmid: 15751910
references.citation: N Engl J Med. 2012 Oct 25;367(17):1577-9
references.pmid: 23050510
references.citation: Diabetes Obes Metab. 2010 Oct;12(10):876-82
references.pmid: 20920040
references.citation: Clin Pharmacol Ther. 2006 May;79(5):500-8
references.pmid: 16678551
references.citation: Drugs. 1998 Dec;56(6):1093-124
references.pmid: 9878996
references.citation: Obesity (Silver Spring). 2010 Jan;18(1):108-15
references.pmid: 19461584
references.citation: Ann Intern Med. 1993 Oct 1;119(7 Pt 2):707-13
references.pmid: 8363202
references.citation: N Engl J Med. 2001 Sep 13;345(11):790-7
references.pmid: 11556298
references.citation: Arch Intern Med. 2004 May 10;164(9):994-1003
references.pmid: 15136309
references.citation: Nat Med. 1998 Oct;4(10):1152-6
references.pmid: 9771748
references.citation: Nat Neurosci. 2005 May;8(5):585-9
references.pmid: 15856067
references.citation: Ann Intern Med. 2004 May 18;140(10):769-77
references.pmid: 15148063
references.citation: Obes Rev. 2000 Oct;1(2):127-39
references.pmid: 12119986
references.citation: Neurosci Biobehav Rev. 2002 Jun;26(4):393-428
references.pmid: 12204189
references.citation: Diabetes Care. 2003 Jan;26(1):125-31
references.pmid: 12502668
references.citation: Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):187-93
references.pmid: 18991793
references.citation: Drug Saf. 2006;29(4):277-302
references.pmid: 16569079
references.citation: Clin Pharmacol Ther. 2010 Jul;88(1):69-78
references.pmid: 20520602
references.citation: Lancet. 2006 Nov 11;368(9548):1660-72
references.pmid: 17098084
references.citation: Int J Obes Relat Metab Disord. 1997 Jun;21 Suppl 3:S12-23
references.pmid: 9225172
references.citation: World J Diabetes. 2011 Feb 15;2(2):19-23
references.pmid: 21537456
references.citation: Am J Cardiol. 2007 Dec 17;100(12A):18P-26P
references.pmid: 18154742
references.citation: Obesity (Silver Spring). 2012 Jul;20(7):1426-36
references.pmid: 22421927
references.citation: Neurology. 2008 Jul 22;71(4):272-6
references.pmid: 18645165
references.citation: Eur J Endocrinol. 2009 Nov;161(5):655-62
references.pmid: 19729432
references.citation: Ann Intern Med. 2005 Apr 5;142(7):532-46
references.pmid: 15809465
references.citation: Am J Physiol Regul Integr Comp Physiol. 2004 May;286(5):R803-13
references.pmid: 15068965
references.citation: Circulation. 2002 Feb 19;105(7):804-9
references.pmid: 11854119
references.citation: Diabetes Care. 2001 Nov;24(11):1957-60
references.pmid: 11679464
references.citation: Arch Intern Med. 1984 Jun;144(6):1143-8
references.pmid: 6375610
references.citation: Diabetes Care. 2004 Jan;27(1):155-61
references.pmid: 14693982
references.citation: Ann N Y Acad Sci. 1998 Dec 15;861:74-8
references.pmid: 9928241
references.citation: Br J Clin Pharmacol. 2009 Dec;68(6):804-10
references.pmid: 20002075
references.citation: Lancet. 1998 Mar 21;351(9106):853-6
references.pmid: 9525361
references.citation: N Engl J Med. 1997 Aug 28;337(9):581-8
references.pmid: 9271479
references.citation: Endocr Pract. 2006 Jan-Feb;12(1):18-28
references.pmid: 16524859
references.citation: Int J Obes Relat Metab Disord. 2004 Nov;28(11):1411-9
references.pmid: 15356670
references.citation: Mol Pharmacol. 2000 Jan;57(1):75-81
references.pmid: 10617681
references.citation: Obes Res. 2000 Dec;8(9):673-5
references.pmid: 11225716
references.citation: Mov Disord. 2004 Oct;19(10):1183-6
references.pmid: 15390018
references.citation: Expert Opin Pharmacother. 2008 Jul;9(10):1629-39
references.pmid: 18570597
references.citation: Handb Exp Pharmacol. 2012;(209):433-66
references.pmid: 22249827
references.citation: Lancet. 2008 Nov 29;372(9653):1906-1913
references.pmid: 18950853
references.citation: Circulation. 1983 May;67(5):968-77
references.pmid: 6219830
references.citation: N Engl J Med. 2005 Nov 17;353(20):2121-34
references.pmid: 16291982
references.citation: Lancet. 2009 Nov 7;374(9701):1606-16
references.pmid: 19853906
references.citation: Int J Obes (Lond). 2007 Mar;31(3):494-9
references.pmid: 16953261
references.citation: Nature. 1995 Apr 6;374(6522):542-6
references.pmid: 7700379
references.citation: Obes Res. 2000 Jan;8(1):71-82
references.pmid: 10678261
references.citation: Diabet Med. 2002 Feb;19(2):119-24
references.pmid: 11874427
references.citation: Nat Med. 2002 Oct;8(10):1129-35
references.pmid: 12244304
references.citation: Int J Obes (Lond). 2005 May;29(5):509-16
references.pmid: 15685250
references.citation: Ann Intern Med. 2005 Apr 5;142(7):525-31
references.pmid: 15809464
references.citation: Ann Epidemiol. 2012 May;22(5):349-53
references.pmid: 22305325
references.citation: N Engl J Med. 2008 Oct 9;359(15):1577-89
references.pmid: 18784090
references.citation: Drug Saf. 2011 Aug 1;34(8):641-50
references.pmid: 21751825
references.citation: Lancet. 2005 Apr 16-22;365(9468):1389-97
references.pmid: 15836887
references.citation: Diabetes. 2008 Mar;57(3):783-90
references.pmid: 18162505
references.citation: Am J Med. 2006 Aug;119(8):e7
references.pmid: 16887401
references.citation: Congest Heart Fail. 2005 May-Jun;11(3):118-23
references.pmid: 15947531
references.citation: N Engl J Med. 2010 Jul 15;363(3):245-56
references.pmid: 20647200
references.citation: Eur J Cardiovasc Prev Rehabil. 2004 Feb;11(1):3-8
references.pmid: 15167200
references.citation: Eur Heart J. 2007 Dec;28(23):2915-23
references.pmid: 17595194